Proteomics based diagnostic detection method for chronic sinusitis
View Patent ↗The invention provides for a proteomic approach for identification of specific bacterial protein profiles that may be used in the development of methods for the diagnosis of bacterial chronic sinusitis. The invention provides for methods for determining the presence of pathogenic bacteria in the upper respiratory tract of a subject using protein profiles of the pathogenic bacteria. The invention also provides for methods of diagnosing a bacterial infection of the upper respiratory tract of a subject using protein profiles of a pathogenic bacteria. In addition, the invention provides for devices, immunoassays and kits for identifying pathogenic bacteria in the upper respiratory tract.
1. A method of detecting the presence of nontypeable Haemophilus influenzae (NTHI) bacteria in the upper respiratory tract of a subject comprising the steps of:
a) obtaining a sample of secretions from the upper respiratory tract of the subject by inserting a collection device into the nasopharynx or middle meatus of the subject; and
b) detecting the presence of at least one biomarker in the sample, wherein the biomarker is OMP P2 or OMP P5 by contacting the sample with antibodies specific for OMP P2 or OMP P5.
2. The method of claim 1 further comprising the step of informing the subject of the presence or absence of NTHI bacteria in the upper respiratory tract of the subject.
3. The method of claim 2 further comprising the step of administering a therapeutic compound to reduce or eliminate the NTHI bacteria in the upper respiratory tract of the subject.
4. An immunoassay method for detecting the presence of a nontypeable Haemeophilus influenza (NTHI) bacteria in the upper respiratory tract of a subject; the method comprising the steps of:
a) obtaining a sample of secretions from the upper respiratory tract of the subject using a device by inserting the device into the subject's middle meatus or nasopharynx;
b) contacting the sample with a substrate onto which antibodies specific for at least one biomarker associated with the presence of a NTHI bacteria in the upper respiratory tract of the subject have been immobilized, wherein at least one biomarker is OMP P2 or OMP P5;
c) contacting the sample with labeled antibodies specific for the at least one biomarker associated with the presence of a NTHI bacteria in the upper respiratory tract of the subject; and
d) detecting the labeled antibody.
5. The immunoassay method of claim 4 further comprising the step of administering a therapeutic compound in an amount effective to treat the bacterial infection.